MedTrace Logo

Pharmacokinetic/Pharmacodynamic Study of Vicagrel Capsules and Clopidogrel Tablets in Healthy CYP2C19 Normal Metabolizers

NCT07067775 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2025-09-09

No results posted yet for this study

Summary

This clinical study will adopt an open-label, randomized, two-crossover design to explore the pharmacokinetic and pharmacodynamic profiles of Vicagrel Capsules and Clopidogrel Tablets in Healthy Subjects with CYP2C19 Normal Metabolizers

Conditions

  • Acute Coronary Syndrome

Interventions

DRUG

Vicagrel Capsules

Vicagrel Capsules qd per period, for two periods

DRUG

Clopidogrel Tablets

Clopidogrel Tablets qd per period, for two periods

Sponsors & Collaborators

  • Jiangsu vcare pharmaceutical technology co., LTD

    lead INDUSTRY

Principal Investigators

  • Xiaojiao Li · The First Hospital of Jilin University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-08-05
Primary Completion
2025-08-22
Completion
2025-08-22

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07067775 on ClinicalTrials.gov